By Dr. Jinhag Baik (백진학), ophthalmologist and head director, Nunehim Eye Center (눈에힘안과의원), Guro-gu, Seoul. Educational article based on published studies and U.S. prescribing information, November 2026.
If you have been prescribed cyclosporine drops for dry eye, you may already have asked one of these questions: “I’ve used them for a month and I can’t tell the difference from artificial tears.” “They burn every time. Should I keep going?” “Can I stop once I feel better?”
Short answer: cyclosporine is not a drop that makes your eyes feel wet right away. It works on inflammation of the eye’s surface, so improvement builds over weeks to months. The main trials judged results at one to six months. A month is usually too early to decide that the drops have failed. Burning is the most common side effect, and it is worth discussing before you stop on your own.
Key points
- Cyclosporine drops are for chronic dry eye in which inflammation appears to be holding back tear production. Doctors usually judge whether they are working at around three months.
- A Cochrane review published in July 2026 (58 randomized trials, 10,225 people) found the drops may improve symptoms and the corneal surface, but the certainty of evidence was low and results varied a lot between studies. They do not give everyone a clear benefit.
- Burning on instillation is the most common side effect (17% in U.S. prescribing information). In trials, people on cyclosporine were more likely to stop because of side effects than people on vehicle drops.
What do cyclosporine eye drops actually do?
They are an immunomodulating drop. They target surface inflammation that can suppress tear production, while artificial tears simply replace moisture.
Dry eye often turns into a cycle. An unstable tear film stresses the eye’s surface, the stress triggers inflammation, and the inflammation makes the tear glands and surface cells work less well. Artificial tears help with the “not enough moisture” part of that cycle. Cyclosporine works on the inflammation.
U.S. prescribing information describes the 0.05% emulsion as a drop to increase tear production in people whose tear production is presumed to be suppressed by ocular inflammation linked to dry eye (keratoconjunctivitis sicca). It is thought to act as a partial immunomodulator in the eye, though the exact mechanism is not known. Inflamed tissue takes time to recover, which is why the effect is slow.
How long do cyclosporine eye drops take to work?
Expect weeks to months. Surface signs may improve within about four weeks, but symptoms and tear volume often change later, and the main trials judged results at three to six months.
| Study | Who | When results were judged | What was found |
|---|---|---|---|
| Sall 2000 (two pooled phase 3 trials) | 877 people, moderate–severe | 6 months | Corneal staining and tear-volume measures better than vehicle |
| Cochrane 2026 (58 trials) | 10,225 people | Mostly 3 months | Possible improvement in symptoms and corneal staining; low certainty |
| Moon 2024 (Korea, single centre) | 35 people, mild–moderate | 4, 8 and 12 weeks | Tear break-up time and staining improved from week 4; Schirmer test unchanged through week 12 |
| ESSENCE-2 2023 (water-free 0.1%) | 834 people, moderate–severe | Day 29 | Slightly better corneal staining than vehicle; dryness scores no different |
| Barber 2005 (long-term extension survey) | Respondents from a 412-person study | Looking back | Most said symptoms began to improve within the first 3 months |
Doses, formulations and severity differ between studies, so the time points are not directly comparable.
Three months is a sensible point to assess the drops. It is not a point at which improvement is guaranteed.
How well do they work? The pivotal trial
In the trials behind U.S. approval, cyclosporine beat vehicle on corneal staining and tear measures. The size of the benefit was modest and showed up only in some patients.
In two identical phase 3 trials (Sall et al., 2000; 877 patients, six months), cyclosporine 0.05% and 0.1% both improved corneal staining and Schirmer categories more than vehicle (the same drop without the active drug). The 0.05% group also did better on blurred vision, artificial-tear use and the doctor’s overall assessment. The higher dose did not work better.
U.S. prescribing information summarises the tear result this way: at six months, about 15% of cyclosporine-treated patients had an increase of 10 mm or more on the Schirmer test, compared with about 5% on vehicle. The label also notes that this increase was not seen in people already using topical anti-inflammatory drugs or punctal plugs.
What the 15% does not mean: it is not the share of people who improved at all. It is the share whose tear production went up by a large amount. Smaller improvements in comfort or surface health are not counted in it. It also means you should not expect a big jump in tear volume.
What did the 2026 Cochrane review conclude?
Possible benefit, low-certainty evidence, and inconsistent results.
The July 2026 Cochrane update (Priyadarshini et al.) pooled 58 randomized trials with 10,225 participants. Sixty percent of the trials came from South Korea, the USA and China. Most followed patients for about three months.
| Comparison | Finding at ~3 months | Certainty |
|---|---|---|
| 0.05% vs vehicle/artificial tears: symptoms | May improve (SMD −0.33), very inconsistent between studies (I² 86%) | Low |
| 0.05% vs vehicle/artificial tears: corneal staining | May improve (SMD −0.20) | Low |
| 0.05%: stopping because of side effects | About twice as likely (RR 1.99) | Moderate |
| 0.1% vs vehicle/artificial tears: corneal and conjunctival staining | Probably improves (SMD −0.16 and −0.20) | Moderate |
| Newer formulations/concentrations vs 0.05% | Mostly imprecise; more stopping due to side effects (RR 1.72) | Low–moderate |
SMD is a standardised effect size; about 0.2 is usually read as small and 0.5 as moderate.
The authors called for future trials that separate dry eye by subtype and severity and that look at long-term benefits and harms. A separate 2025 meta-analysis of 48 trials (Chidi-Egboka et al.) also found that cyclosporine may outperform vehicle or artificial tears, again with low-to-moderate certainty and some inconsistency.
Low-certainty evidence does not mean the drops don’t work. It means nobody can say confidently how much they help, and the answer probably differs between someone whose dry eye is mainly inflammatory and someone whose main problem lies elsewhere.
Are the newer formulations better?
There is no clear evidence that they beat the original 0.05% emulsion.
Several formulations exist: a 0.1% cationic emulsion used once daily, a water-free 0.1% solution, nanoemulsions and others. In the SANSIKA trial (246 people with severe dry eye, six months), the 0.1% cationic emulsion improved corneal damage and a marker of surface inflammation, but it did not meet its combined sign-and-symptom primary endpoint (28.6% vs 23.1%), and instillation pain was more common (29.2% vs 8.9%). In ESSENCE-2, the water-free solution improved staining slightly at day 29 (71.6% vs 59.7% reached a 3-grade improvement), but dryness scores did not differ from vehicle. A 2026 Korean phase 2 trial found low-concentration (0.01–0.02%) nanoparticle drops similar to 0.05% at 12 weeks. That is encouraging, but it is not proof that they are better.
Why do they sting, and what can be done?
Burning is the most common side effect. It is usually mild, and it is also a common reason people stop.
| Source | Burning / pain |
|---|---|
| U.S. prescribing information (0.05%) | Ocular burning 17% (most common) |
| SANSIKA 2016 (0.1% cationic) | Instillation pain 29.2% vs 8.9% on vehicle |
| Barber 2005 (0.1%, up to 3 years, 412 people) | Burning 10.9%, stinging 3.9%, redness 3.4% |
One randomized trial (Sheppard 2014, 118 patients) gave a two-week course of a steroid drop before starting cyclosporine. Stinging was significantly lower, and signs and symptoms improved faster. Steroid drops can raise eye pressure, though, so whether that approach suits you is a decision for your ophthalmologist, not something to try with leftover drops.
Other side effects, contact lenses and pregnancy
Per U.S. prescribing information for the 0.05% emulsion:
- Contraindication: known or suspected hypersensitivity to any ingredient.
- 1–5% of patients: redness, discharge, watering, eye pain, foreign-body sensation, itching, stinging, blurred vision.
- Contact lenses: remove them before using the drops. You can put them back in 15 minutes later.
- With artificial tears: they can be used together; leave 15 minutes between drops.
- Children: safety and effectiveness have not been established under age 16.
- Pregnancy: the drug was not detected in the blood after use in the eye, and fetal exposure is not expected. Still, tell your doctor if you are pregnant, breastfeeding or planning a pregnancy.
- Long-term use: in a study lasting up to three years (mean 19.8 months), there were no serious treatment-related or systemic adverse events.
Products and labels in Korea may differ, so read the leaflet that comes with your prescription.
How do they compare with other dry eye treatments?
| Treatment | What it does | Typical use in the cited studies | Main caution |
|---|---|---|---|
| Artificial tears (e.g., hyaluronic acid) | Adds moisture and lubrication | Immediate but temporary relief | Does not change the underlying cause |
| Diquafosol drops | Stimulates tear and mucin secretion | 6 times a day; assessed at 4–12 weeks | Frequent dosing |
| Cyclosporine drops | Calms surface inflammation | 1–2 times a day; assessed at 1–6 months | Stinging; needs consistency |
| Steroid drops | Strong anti-inflammatory | Studied for 1 week to 3 months | Eye pressure must be monitored |
| Warm compresses, lid care, IPL | Improve meibomian gland function | Repeated regularly | IPL only when suitable |
Cyclosporine versus diquafosol: two 2026 meta-analyses (724 and 859 patients) found no clear winner. Cyclosporine had a small edge on tear-volume testing and diquafosol a small edge on symptom scores. A Korean observational study (Eom 2022, 279 patients) saw a larger gain in tear break-up time when the two were combined, but it was not randomized. A 2022 Cochrane review of steroid drops (22 trials, 4,169 people) found small-to-moderate symptom relief compared with lubricants, with a higher rate of eye-pressure rises (RR 5.96), though the evidence on that harm was very uncertain.
If your dry eye is mainly evaporative (meibomian gland dysfunction), cyclosporine alone may not be enough. See our guides on winter heating and evaporative dry eye, warm compresses and IPL sessions.
How long should you use them, and when can you stop?
There is no evidence-based stopping date. Assess at around three months. If they help, they are often continued, and any taper should follow a re-examination.
In a U.S. claims study (White 2019, 6,537 patients on cyclosporine 0.05%), 70.8% stopped within a year, with a median time to stopping of 89 days. That is roughly the point at which benefit is usually assessed. The data did not show why people stopped. The 2026 Cochrane review also noted that long-term benefits and harms have not been well studied. Stopping as soon as you feel better is not the best plan. Ask for a repeat surface exam (staining, tear break-up time, Schirmer test) before deciding together.
Practical tips for busy office workers in Seoul
- Fix the times: 12 hours apart, for example 7–8 a.m. and 7–8 p.m., with phone alarms.
- Contact lens wearers: drop first, wait 15 minutes, then put your lenses in.
- Single-use vials: invert a few times before use, use right after opening, and throw away what is left.
- Winter offices: keep heater vents from blowing on your face. The drops work more slowly if your environment keeps drying your eyes.
- Keep a short log at the start, week 4 and week 12 (worst time of day, number of artificial tears used) to bring to your follow-up.
- If the stinging is bad, tell your doctor rather than quietly stopping.
Frequently asked questions
I’ve used them for a month with no change. Should I switch?
A month is often too early. Key studies judged results at three to six months. If burning is severe or your eyes are getting worse, though, get checked sooner.
Are cyclosporine drops better than artificial tears?
Not necessarily. They do a different job, and most people use both. The 2026 Cochrane review rated the advantage over vehicle or artificial tears as possible but low-certainty.
It’s an immunosuppressant. Is it safe for my body?
After use in the eye, the drug was not detected in the bloodstream, and a study lasting up to three years reported no systemic side effects. Still, tell your doctor about your other medicines and medical conditions.
Can I use them with contact lenses?
Not while the lenses are in. Wait 15 minutes after the drop before putting them back in.
I have meibomian gland dysfunction. Will these drops fix it?
Probably not on their own. Gland-focused care (warm compresses, lid hygiene and, when suitable, IPL) comes first, and cyclosporine may be added if inflammation is part of the picture.
Are the newer formulations faster?
Some improved surface staining within a month, but symptom scores did not beat vehicle, and the 2026 Cochrane review found no clear advantage over 0.05%.
Bottom line
Cyclosporine drops are a slow, long-term treatment for inflammatory dry eye. Use them consistently for about three months, judge the result with an exam rather than a feeling, and raise stinging with your doctor before giving up. The evidence supports a modest benefit for some people, not a dramatic one for everyone.
Nunehim Eye Center (눈에힘안과의원)
Head director: Dr. Jinhag Baik, ophthalmologist
Address: 5F, 551 Siheung-daero, Guro-gu, Seoul (a short walk from Guro Digital Complex Station, near Gasan Digital Complex)
Website: https://www.nunehim.com
Related reading: Is there a pill for dry eye? Oral pilocarpine · Punctal plugs for dry eye
This article is general health education based on studies and prescribing information available as of November 2026. It is not a recommendation for any specific prescription product and does not replace an individual examination. Results and side effects vary from person to person.
References
- Priyadarshini SR, et al. Topical cyclosporine A therapy for dry eye disease. Cochrane Database Syst Rev. 2026;7:CD010051. https://pubmed.ncbi.nlm.nih.gov/42464966/
- Sall K, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000;107(4):631–639. https://pubmed.ncbi.nlm.nih.gov/10768324/
- U.S. prescribing information, cyclosporine ophthalmic emulsion 0.05% (generic, DailyMed, revised 3/2024). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc64c1e3-19f5-4bf6-a08d-a9725004c97f
- Leonardi A, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26(4):287–296. https://pubmed.ncbi.nlm.nih.gov/27055414/
- Akpek EK, et al. Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for moderate to severe dry eye disease: the ESSENCE-2 randomized clinical trial. JAMA Ophthalmol. 2023;141(5):459–466. https://pubmed.ncbi.nlm.nih.gov/37022717/
- Barber LD, et al. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005;112(10):1790–1794. https://pubmed.ncbi.nlm.nih.gov/16102833/
- Sheppard JD, et al. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens. 2014;40(5):289–296. https://pubmed.ncbi.nlm.nih.gov/25083776/
- White DE, et al. Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye. Clin Ophthalmol. 2019;13:2285–2292. https://pubmed.ncbi.nlm.nih.gov/31819353/
- Chidi-Egboka NC, et al. Evidence on the use of topical ciclosporin for ocular surface disease: a systematic review and meta-analysis. Clin Exp Ophthalmol. 2025;53(5):470–492. https://pubmed.ncbi.nlm.nih.gov/40056051/
- Chen KY, et al. Efficacy of topical cyclosporine versus topical diquafosol in treating dry eye disease: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2026;42(6):347–355. https://pubmed.ncbi.nlm.nih.gov/41804812/
- Alsuhail AY, et al. Comparative efficacy and safety of 0.05% cyclosporine A and 3% diquafosol sodium in dry eye disease. J Clin Med. 2026;15(12):4823. https://pubmed.ncbi.nlm.nih.gov/42355991/
- Liu SH, et al. Topical corticosteroids for dry eye. Cochrane Database Syst Rev. 2022;10:CD015070. https://pubmed.ncbi.nlm.nih.gov/36269562/
- Moon SY, et al. Effectiveness of cyclosporine nanoemulsion eye drops in patients with mild-to-moderate dry eyes. BMC Ophthalmol. 2024;24(1):401. https://pubmed.ncbi.nlm.nih.gov/39251947/
- Kim JH, et al. Comparative study on the clinical effectiveness of low-concentration cyclosporine eye drops in patients with dry eye disease. PLoS One. 2026;21(9):e0358007. https://pubmed.ncbi.nlm.nih.gov/42804440/
- Eom Y, et al. Effectiveness of topical cyclosporin A 0.1%, diquafosol tetrasodium 3%, and their combination, in dry eye disease. J Ocul Pharmacol Ther. 2022;38(10):682–694. https://pubmed.ncbi.nlm.nih.gov/36473191/
Leave a Reply